Study Overview
Let's Talk About It
The Time is Now
Mitapivat is a potential new therapy for the pain crises and anemia of sickle cell disease. There have been two studies for mitapivat so far — a smaller phase 1 study and a phase 2 study. Now the next part of RISE UP, a phase 3 study, is enrolling Warriors.
How Rise Up Works
Warriors who enroll in phase 3 will take either mitapivat or placebo twice a day, every day, for one year. After that, participants can choose to continue taking mitapivat, or switch from placebo to mitapivat, for up to four years (216 weeks) as part of the open-label extension period of the study.
PHASE 3 (Now Enrolling)
How Mitapivat May Work
Learn about the potential benefits and risks of mitapivat and the goal of the RISE UP clinical trial.
GET READY FOR THE NEXT PHASE OF RISE UP
Learn more about RISE UP, including full enrollment details, all study objectives, and key inclusion and exclusion details. Then talk to your eligible patients about the study.
If you have questions, email:
medinfo@agios.com (US)
ex-usmedinfo@agios.com (outside US)
